Results 11 to 20 of about 4,650 (177)
Korean Journal of Clinical Laboratory Science, 2023 Sepsis is a systemic inflammatory response, with manifestations in multiple organs by pathogenic infection. Currently, there are no promising therapeutic strategies.
Se Gwang JANG
doaj +1 more source
The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR. [PDF]
PLoS Neglected Tropical Diseases, 2018 BACKGROUND:The antiparasitic agent niclosamide has been demonstrated to inhibit the arthropod-borne Zika virus. Here, we investigated the antiviral capacity of niclosamide against dengue virus (DENV) serotype 2 infection in vitro and in vivo.
Jo-Chi Kao +8 more
doaj +1 more source
Cell Death and Disease, 2022 Niclosamide, a cell-permeable salicylanilide, was approved by the Food and Drug Administration for its anthelmintic efficiency. A growing body of evidence in recent years suggests that niclosamide exhibits potential tumor-suppressive activity.
Yangyang Guo +9 more
doaj +1 more source
Metabolomic analyses uncover an inhibitory effect of niclosamide on mitochondrial membrane potential in cholangiocarcinoma cells [PDF]
PeerJ, 2023 Background Niclosamide is an oral anthelminthic drug that has been used for treating tapeworm infections. Its mechanism involves the disturbance of mitochondrial membrane potential that in turn inhibits oxidative phosphorylation leading to ATP depletion.
Thanaporn Kulthawatsiri +9 more
doaj +2 more sources
AAPS Open, 2023 Motivation The low solubility, weak acid drug, niclosamide is a host cell modulator with broad-spectrum anti-viral cell-activity against many viruses, including stopping the SARS-CoV-2 virus from infecting cells in cell culture.
David Needham
doaj +1 more source
The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. [PDF]
PLoS ONE, 2014 Breast carcinoma is the most common female cancer with considerable metastatic potential. Discovery of new therapeutic approaches for treatment of metastatic breast cancer is still needed.
Tinghong Ye +12 more
doaj +1 more source
Pharmaceutics, 2022 Niclosamide is an FDA-approved anthelmintic that is being studied in clinical trials as a chemotherapeutic and broad-spectrum antiviral. Additionally, several other applications are currently in the preclinical stage.
Miguel O. Jara +7 more
doaj +1 more source
Niclosamide—A promising treatment for COVID‐19 [PDF]
British Journal of Pharmacology, 2022 Vaccines have reduced the transmission and severity of COVID‐19, but there remains a paucity of efficacious treatment for drug‐resistant strains and more susceptible individuals, particularly those who mount a suboptimal vaccine response, either due to underlying health conditions or concomitant therapies.
Shivani Singh +9 more
openaire +2 more sources
Investigation of niclosamide as a repurposing agent for skeletal muscle atrophy.
PLoS ONE, 2021 Skeletal muscle atrophy is a feature of aging (termed sarcopenia) and various diseases, such as cancer and kidney failure. Effective drug treatment options for muscle atrophy are lacking.
Hyun-Jun Kim +5 more
doaj +1 more source
In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 Treatment
Vaccines, 2022 Niclosamide, an FDA-approved oral anthelmintic drug, has broad biological activity including anticancer, antibacterial, and antiviral properties. Niclosamide has also been identified as a potent inhibitor of SARS-CoV-2 infection in vitro, generating ...
Jesse W. Wotring +11 more
doaj +1 more source